Fig. 6: mTOR inhibits ATF4 degradation via the ubiquitin‒proteasome pathway.

a At different time points after treatment with CHX, human primary meniscal cell lysates were analyzed via WB for the indicated proteins. b Quantification of the WB data; n = 3. c Human primary meniscal cells were treated with the indicated drugs for 24 h; WB analysis of Ub and ATF4 was performed using protein isolated from the ATF4 immunoprecipitate or total lysate. d Quantification of the WB data; n = 3. The data are expressed as the mean ± SD; *P < 0.05; **P < 0.01; and ***P < 0.001. One-way ANOVA was used for comparisons.